Lonza Group expands dual-payload ADC offering; stock pre-market at EUR 615.70
Published on 10/13/2026 at 08:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Lonza announced an exclusive CDK7 inhibitor license agreement with Qurient on October 12, 2026.
- The agreement adds dual-payload ADC technology, including SYN-duo CC, to Lonza’s offering.
- Lonza stock was at EUR 615.70 in pre-market trading at 8:38 a.m. CEST on October 13, 2026.
On October 12, 2026, EQS News reported that Lonza Group had entered an exclusive license agreement with Qurient for the use of CDK7 inhibitors in dual-payload antibody-drug conjugate applications. The release identifies Lonza Group AG as the issuer and gives its ISIN as CH0013841017.
Pre-market trading
Lonza stock was at EUR 615.70 at Lang & Schwarz on October 13, 2026, at 8:38 a.m. CEST. The bid was EUR 614.40 and the ask was EUR 617.00. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Lonza Group stock.
Expanded ADC technology offering
The agreement adds CDK7 inhibitor technology to Lonza’s dual-payload ADC toolbox. The company said the initial product under the collaboration, SYN-duo CC, combines exatecan with Qurient’s CDK7 inhibitor to provide an off-the-shelf linker-payload for ADC design and development. Lonza also said its existing platform could support additional combinations of the CDK7 inhibitor with other payloads. EQS News said the agreement supports Lonza’s strategy of expanding proprietary technologies within its integrated CDMO services.
Market context: Market report SMI.
